EQS-News

"In Europe, For Europe": Haier Biomedical Spotlights Full-Scenario Lab Solutions at analytica Munich 2026 10.04.2026, 10:45 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Haier Biomedical / Key word(s): Miscellaneous
"In Europe, For Europe": Haier Biomedical Spotlights Full-Scenario Lab Solutions at analytica Munich 2026

10.04.2026 / 10:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


MUNICH, April 10, 2026 /PRNewswire/ -- Haier Biomedical, a global leader in life sciences and medical solutions, presented its fullscenario laboratory solutions at analytica 2026 in Munich under the theme "In Europe, For Europe." The exhibition underscores the company's deepening localization strategy across Europe, backed by its regional operations network and recent milestones in key European markets.

Haier Biomedical is evolving from a traditional equipment supply to become a comprehensive provider of laboratory scenario solutions, delivering end-to-end solutions for biobanks, research labs, and pharmacies, spanning collection, storage, monitoring, and management.

At analytica 2026, Haier Biomedical showcased a comprehensive portfolio of life sciences equipment, including CO₂ Incubators, Biosafety Cabinets, Centrifuges, Pharmacy Refrigerators, Liquid Nitrogen Containers, Autoclaves, and the newly launched Incubator Shakers, designed for cell suspension culture with continuous oscillation and precise temperature control, as well as the Freeze Dryer for efficient sample drying.

Among the exhibited innovations and solutions, the UltraEco ULT Freezer series featured Eco-Drive technology, is now able to deliver 30% higher efficiency than industry benchmarks.

In addition to the Biobanking Solution showcased at this event, Haier Biomedical now delivers fully integrated and automated workflows spanning sample collection, storage, and monitoring. These solutions effectively address real-world challenges in sample integrity, operational efficiency, and data traceability.

For Haier Biomedical, globalization is not just a single-direction export of products but to cultivating and deepening roots in the local markets. It has taken a "one country, one strategy" approach and established localized operations in 18 countries worldwide, obtaining over 400 local product certifications, with local teams accounting for more than 40% of its global workforce.

This approach has enabled Haier Biomedical to achieve the No. 1 market share among Chinese brands in six countries, including Italy, where the Company plans to establish a subsidiary to further strengthen its local service capabilities for industry users and deliver more comprehensive value across the region.

In the UK, Haier Biomedical has completed end-to-end delivery of 64 customized Biosafety Cabinets to Queen Mary University of London within 24 hours; in Italy, it has provided a customized U-Blood intelligent blood management system for local hospital, introducing a smart blood management solution into the European healthcare system; while in Germany, it has supplied -150°C Cryo Freezers and BPST ULT Freezers to local leading universities, which combined hydrocarbon refrigeration technology with ultra-quiet operation to improve research safety and efficiency.

Analytica 2026 marks the fundamental strategic shift of Haier Biomedical from product exports to ecosystem co-creation. Haier Biomedical is charting a new chapter in the globalization of this life science company with its 'technology + local presence + ecosystem' model. Looking ahead, Haier Biomedical will continue to deepen roots in the European market, empowering global expansion through local strength and striving to become a trusted life science brand for users worldwide.

For more information, please visit https://www.haiermedical.com/.

Video - https://mma.prnewswire.com/media/2953687/Video1.mp4
Video - https://mma.prnewswire.com/media/2953686/Video_2.mp4

Cision View original content:https://www.prnewswire.co.uk/news-releases/in-europe-for-europe-haier-biomedical-spotlights-full-scenario-lab-solutions-at-analytica-munich-2026-302739128.html

rt.gif?NewsItemId=EN31470&Transmission_Id=202604100440PR_NEWS_EURO_ND__EN31470&DateId=20260410


10.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2306478  10.04.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 21:48 Uhr • Artikel • dpa-AFX

Gestern 21:48 Uhr • Artikel • dpa-AFX

Gestern 21:48 Uhr • Artikel • dpa-AFX

Gestern 20:56 Uhr • Artikel • dpa-AFX

Gestern 20:40 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer